CY2021036I1 - Αντισωματα anti-angptl3 και χρησεις αυτων - Google Patents

Αντισωματα anti-angptl3 και χρησεις αυτων

Info

Publication number
CY2021036I1
CY2021036I1 CY2021036C CY2021036C CY2021036I1 CY 2021036 I1 CY2021036 I1 CY 2021036I1 CY 2021036 C CY2021036 C CY 2021036C CY 2021036 C CY2021036 C CY 2021036C CY 2021036 I1 CY2021036 I1 CY 2021036I1
Authority
CY
Cyprus
Prior art keywords
angptl3 antibodies
angptl3
antibodies
Prior art date
Application number
CY2021036C
Other languages
English (en)
Other versions
CY2021036I2 (el
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46298728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2021036(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY2021036I1 publication Critical patent/CY2021036I1/el
Publication of CY2021036I2 publication Critical patent/CY2021036I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY2021036C 2011-06-17 2021-12-06 Αντισωματα anti-angptl3 και χρησεις αυτων CY2021036I2 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498518P 2011-06-17 2011-06-17
US201161578309P 2011-12-21 2011-12-21

Publications (2)

Publication Number Publication Date
CY2021036I1 true CY2021036I1 (el) 2022-03-24
CY2021036I2 CY2021036I2 (el) 2022-05-27

Family

ID=46298728

Family Applications (2)

Application Number Title Priority Date Filing Date
CY181101324T CY1120996T1 (el) 2011-06-17 2018-12-11 Αντισωματα anti-angptl3 και χρησεις αυτων
CY2021036C CY2021036I2 (el) 2011-06-17 2021-12-06 Αντισωματα anti-angptl3 και χρησεις αυτων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY181101324T CY1120996T1 (el) 2011-06-17 2018-12-11 Αντισωματα anti-angptl3 και χρησεις αυτων

Country Status (46)

Country Link
US (7) US9018356B2 (el)
EP (2) EP3418301A1 (el)
JP (2) JP6400471B2 (el)
KR (1) KR102031007B1 (el)
CN (1) CN103732624B (el)
AR (1) AR087329A1 (el)
AU (1) AU2012271663B2 (el)
CA (1) CA2838867C (el)
CL (1) CL2013003552A1 (el)
CO (1) CO6821892A2 (el)
CR (1) CR20130621A (el)
CY (2) CY1120996T1 (el)
DK (1) DK2721065T3 (el)
DO (1) DOP2013000299A (el)
EC (1) ECSP13013085A (el)
ES (1) ES2699499T3 (el)
FI (1) FIC20210028I1 (el)
FR (1) FR21C1061I2 (el)
GT (1) GT201300306A (el)
HR (1) HRP20182098T1 (el)
HU (1) HUS2100034I1 (el)
IL (2) IL229612B (el)
JO (1) JO3412B1 (el)
LT (2) LT2721065T (el)
LU (1) LUC00231I2 (el)
MA (1) MA35190B1 (el)
MX (2) MX337644B (el)
MY (1) MY160516A (el)
NI (1) NI201300136A (el)
NL (1) NL301122I2 (el)
NO (2) NO2021037I1 (el)
PE (1) PE20141166A1 (el)
PH (1) PH12013502570B1 (el)
PL (1) PL2721065T3 (el)
PT (1) PT2721065T (el)
RS (1) RS58310B1 (el)
RU (1) RU2620064C2 (el)
SG (1) SG195165A1 (el)
SI (1) SI2721065T1 (el)
SM (1) SMT201800658T1 (el)
TR (1) TR201816591T4 (el)
TW (3) TW201815822A (el)
UA (1) UA114891C2 (el)
UY (2) UY34137A (el)
WO (1) WO2012174178A1 (el)
ZA (1) ZA201308879B (el)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2017011929A1 (zh) * 2015-07-17 2017-01-26 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
AU2017219602C1 (en) * 2016-02-17 2024-05-09 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing atherosclerosis by administering an inhibitor of ANGPTL3
CA3016764A1 (en) * 2016-03-03 2017-09-08 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
ES2896107T3 (es) 2016-04-08 2022-02-23 Regeneron Pharma Métodos para tratar la hiperlipidemia con un inhibidor de ANGPTL8 y un inhibidor de ANGPTL3
PT3448426T (pt) * 2016-04-28 2025-06-04 Regeneron Pharma Métodos para tratamento de pacientes com hipercolesterolemia familiar
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
KR20190078650A (ko) 2016-11-17 2019-07-04 리제너론 파아마슈티컬스, 인크. 항-angptl8 항체를 사용하는 비만의 치료 방법
EP3649144A4 (en) 2017-07-06 2021-07-21 Regeneron Pharmaceuticals, Inc. CELL CULTURE PROCESS TO PRODUCE GLYCOPROTEIN
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
US20190194298A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
SG11202005235WA (en) 2018-01-31 2020-07-29 Regeneron Pharma System and method for characterizing size and charge variant drug product impurities
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
MX2020008988A (es) 2018-02-28 2020-09-28 Regeneron Pharma Sistemas y metodos para la identificacion de contaminantes virales.
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
FI3768709T3 (fi) 2018-03-19 2024-02-01 Regeneron Pharma Mikrosirukapillaarielektroforeesianalyysejä ja -reagensseja
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
IL317123A (en) 2018-08-27 2025-01-01 Regeneron Pharma Using Raman Spectroscopy for Downstream Purification
CA3100038A1 (en) 2018-08-30 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
CN113396158A (zh) * 2018-11-26 2021-09-14 诺华股份有限公司 Lpl-gpihbp1融合多肽
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
AU2020208396A1 (en) 2019-01-16 2021-05-20 Regeneron Pharmaceuticals, Inc. Methods for identifying free thiols in proteins
WO2020185952A1 (en) * 2019-03-11 2020-09-17 xCella Biosciences, Inc. Cd27-binding antibodies and uses thereof
WO2020231992A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
US20200369760A1 (en) 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies
CN112062845B (zh) * 2019-06-10 2022-09-02 山东博安生物技术股份有限公司 Angptl3结合片段及其用途
WO2021001804A1 (en) * 2019-07-04 2021-01-07 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
US12246305B2 (en) 2019-09-24 2025-03-11 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN119318636A (zh) 2019-11-25 2025-01-17 里珍纳龙药品有限公司 使用非水性乳液的持续释放调配物
CN110938144B (zh) * 2019-11-27 2022-07-26 复旦大学附属儿科医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
WO2021150558A1 (en) 2020-01-21 2021-07-29 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
CN114829395B (zh) * 2020-01-22 2023-12-12 江苏恒瑞医药股份有限公司 抗angptl3抗体及其应用
IL300828A (en) 2020-08-31 2023-04-01 Regeneron Pharma Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants
KR20230113280A (ko) 2020-11-25 2023-07-28 리제너론 파마슈티칼스 인코포레이티드 비수성 멤브레인 유화법을 사용한 지속 방출 제형
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
AU2022230987A1 (en) 2021-03-03 2023-08-31 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
US20240141029A1 (en) * 2021-03-05 2024-05-02 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
AU2022243005A1 (en) 2021-03-26 2023-10-05 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
WO2022205021A1 (zh) * 2021-03-30 2022-10-06 复旦大学附属儿科医院 一种抗angptl3抗体或其抗原结合片段及其制备方法和用途
CA3220848A1 (en) 2021-06-01 2022-12-08 Timothy Riehlman Microchip capillary electrophoresis assays and reagents
AU2022314036A1 (en) * 2021-07-21 2024-02-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application
US20230077710A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
MX2024003411A (es) 2021-09-20 2024-04-30 Regeneron Pharma Métodos para controlar la heterogeneidad de anticuerpos.
EP4413359A1 (en) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
CN118076894A (zh) 2021-10-07 2024-05-24 里珍纳龙药品有限公司 pH建模和控制的系统及方法
CA3236367A1 (en) 2021-10-26 2023-05-04 Michelle Lafond Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
CN116284377A (zh) * 2021-12-21 2023-06-23 复旦大学 抗人血管生成素3纳米抗体及其应用
IL313191A (en) * 2021-12-22 2024-07-01 Regeneron Pharma Treatment of kidney diseases using angiopoietin-like inhibitors 3
EP4493921A1 (en) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2023213779A1 (en) * 2022-05-02 2023-11-09 Novo Nordisk A/S Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
CN117603361A (zh) * 2022-08-22 2024-02-27 复旦大学附属儿科医院 包含angptl3单抗的融合蛋白
CN116143919B (zh) * 2022-11-01 2025-06-13 中国药科大学 全人源抗人nt-angptl3抗体、其抗原结合片段及其应用
US20240198253A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2024130165A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240255519A1 (en) 2023-02-01 2024-08-01 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
WO2024229136A1 (en) 2023-05-01 2024-11-07 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
CN119192369A (zh) * 2023-06-25 2024-12-27 百奥泰生物制药股份有限公司 抗angptl3抗体及其应用
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en) 2023-09-18 2025-03-20 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
WO2025072597A2 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035058A1 (en) 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CA2440355C (en) 2001-02-22 2011-03-08 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
CN1615440A (zh) 2001-11-16 2005-05-11 杰南技术公司 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法
JP2006517785A (ja) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
JP2005080508A (ja) 2003-09-04 2005-03-31 Sankyo Co Ltd 脂質代謝改善剤の試験方法
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US20110097330A1 (en) 2005-03-11 2011-04-28 Genentech, Inc. Novel Gene Disruptions, Compostitions and Methods Relating Thereto
AU2006326417B2 (en) 2005-12-16 2012-05-24 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with Dll4 antagonists
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US7605237B2 (en) * 2006-10-02 2009-10-20 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
AU2007332855B2 (en) * 2006-12-08 2012-08-16 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against ANGPTL3
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
CN101852805B (zh) 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
NZ597306A (en) 2009-07-14 2014-03-28 Scripps Research Inst Mesenchymal stem cell differentiation
AU2011203986C1 (en) 2010-01-08 2015-03-05 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
JP6110372B2 (ja) * 2011-06-21 2017-04-05 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アンジオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及びその使用方法
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
PL3087183T3 (pl) 2013-12-24 2021-01-11 Ionis Pharmaceuticals, Inc. Modulacja ekspresji białka angiopoetynopodobnego 3
CN111961669A (zh) 2014-05-01 2020-11-20 Ionis制药公司 用于调节血管生成素样蛋白3表达的组合物和方法
US10544232B2 (en) 2014-07-16 2020-01-28 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
AU2017219602C1 (en) 2016-02-17 2024-05-09 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing atherosclerosis by administering an inhibitor of ANGPTL3
CA3016764A1 (en) 2016-03-03 2017-09-08 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
ES2896107T3 (es) 2016-04-08 2022-02-23 Regeneron Pharma Métodos para tratar la hiperlipidemia con un inhibidor de ANGPTL8 y un inhibidor de ANGPTL3
PT3448426T (pt) 2016-04-28 2025-06-04 Regeneron Pharma Métodos para tratamento de pacientes com hipercolesterolemia familiar
US20200369760A1 (en) * 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies

Also Published As

Publication number Publication date
DK2721065T3 (en) 2018-12-03
EP2721065B1 (en) 2018-09-12
TR201816591T4 (tr) 2018-11-21
US20220403016A1 (en) 2022-12-22
SG195165A1 (en) 2013-12-30
RU2013155906A (ru) 2015-07-27
CA2838867A1 (en) 2012-12-20
JP6400471B2 (ja) 2018-10-03
AU2012271663B2 (en) 2017-04-20
TW201313738A (zh) 2013-04-01
HRP20182098T1 (hr) 2019-02-08
NI201300136A (es) 2014-05-15
CO6821892A2 (es) 2013-12-31
IL259436A (en) 2018-07-31
DOP2013000299A (es) 2014-04-15
FR21C1061I2 (fr) 2022-11-18
UA114891C2 (uk) 2017-08-28
CR20130621A (es) 2014-02-12
PE20141166A1 (es) 2014-09-16
AU2012271663A1 (en) 2014-01-16
US9018356B2 (en) 2015-04-28
FIC20210028I1 (fi) 2021-09-09
SMT201800658T1 (it) 2019-01-11
LUC00231I2 (el) 2025-02-03
MX2013014345A (es) 2014-01-31
ES2699499T3 (es) 2019-02-11
MY160516A (en) 2017-03-15
IL229612A0 (en) 2014-01-30
LT2721065T (lt) 2018-12-10
KR20140037218A (ko) 2014-03-26
TW201815822A (zh) 2018-05-01
PH12013502570A1 (en) 2014-01-27
SI2721065T1 (sl) 2018-12-31
NO2021037I1 (no) 2021-09-15
MX361859B (es) 2018-12-18
CN103732624B (zh) 2016-08-17
UY39340A (es) 2021-08-31
US20220153825A1 (en) 2022-05-19
ECSP13013085A (es) 2014-01-31
CA2838867C (en) 2020-07-14
NL301122I2 (nl) 2021-12-30
JO3412B1 (ar) 2019-10-20
US20250136675A1 (en) 2025-05-01
TWI644922B (zh) 2018-12-21
US20190315851A1 (en) 2019-10-17
MX337644B (es) 2016-03-14
HUS2100034I1 (hu) 2021-10-28
US20150197564A1 (en) 2015-07-16
CY2021036I2 (el) 2022-05-27
TW201920261A (zh) 2019-06-01
GT201300306A (es) 2015-03-09
CY1120996T1 (el) 2019-12-11
US10358487B2 (en) 2019-07-23
JP2014523739A (ja) 2014-09-18
PL2721065T3 (pl) 2019-02-28
RS58310B1 (sr) 2019-03-29
US20190092845A1 (en) 2019-03-28
EP2721065A1 (en) 2014-04-23
NZ619092A (en) 2016-03-31
EP3418301A1 (en) 2018-12-26
UY34137A (es) 2013-01-03
MA35190B1 (fr) 2014-06-02
ZA201308879B (en) 2014-07-30
IL229612B (en) 2019-06-30
FR21C1061I1 (fr) 2022-01-21
US20130171149A1 (en) 2013-07-04
NO2025028I1 (no) 2025-06-13
CN103732624A (zh) 2014-04-16
PH12013502570B1 (en) 2019-01-16
NL301122I1 (el) 2021-09-01
CL2013003552A1 (es) 2014-07-25
PT2721065T (pt) 2018-12-06
KR102031007B1 (ko) 2019-11-08
RU2620064C2 (ru) 2017-05-22
LTPA2021009I1 (el) 2021-09-27
AR087329A1 (es) 2014-03-19
US9951127B2 (en) 2018-04-24
JP2018166516A (ja) 2018-11-01
LTC2721065I2 (el) 2022-10-25
WO2012174178A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
CY2021036I2 (el) Αντισωματα anti-angptl3 και χρησεις αυτων
CY2020045I1 (el) Anti-pd-l1 αντισωματα και χρησεις αυτων
CY2022019I1 (el) Συνθεσεις αντι-cgrp και χρησεις αυτων
HUS2300021I1 (hu) Anti-IL-36R antitestek
CY2024022I2 (el) Αντιμυκητιασικοι παραγοντες και χρησεις αυτων
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
IL231777B (en) Antibodies against tl1a and uses thereof
IL249650A0 (en) Antibodies directed against icos and uses thereof
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
CO6811812A2 (es) Anticuerpo anti-b7-h3
CO7071096A2 (es) Anticuerpos anti-lgr5 e inmunoconjugados
LT2794654T (lt) Anti-phf-tau antikūnai ir jų panaudojimas
BR112012030311A2 (pt) anticorpo
DK3381943T3 (da) Anti-kit-antistoffer og anvendelser deraf
BR112015002193A2 (pt) anticorpos anti-etbr e imunoconjugados
EP2714735A4 (en) SPECIFIC ANTIBODIES OF TGF BETA
CR20140127A (es) Anticuerpo anti-abtcr
BR112014009050A2 (pt) pirrolbenzodiazepinas e conjugados destas
DK2668210T3 (da) Anti-kit antistoffer og anvendelser deraf
HUE056313T2 (hu) Anti-DLL3 antitest
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
DK2683406T3 (da) Anti-cd40-antistoffer og anvendelser deraf
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
CO6791565A2 (es) Anticuerpos anti-notch1
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf